文献速递产科妇科

不明位置妊娠且异位妊娠高风险女性使用甲氨蝶呤的安全性

Safety of methotrexate administration in women with pregnancy of unknown location at high risk of ectopic pregnancy.
PubMed 文献 · Ultrasound Obstet Gynecol · 2024-06-07

该回顾性观察研究纳入澳大利亚悉尼Nepean医院2007至2021年816例不明位置妊娠(PUL)女性,最终分析724例,评估ACOG、ASRM、RCOG和NICE指南下甲氨蝶呤(MTX)给药的安全性。按各指南MTX给药率分别为2.76%、4.56%、0.41%和35.36%,ACOG和ASRM指南理论上可致4.1/1000(3/724)的潜在存活宫内妊娠误用MTX。作者认为现行指南应审慎使用,PUL女性需密切监测。

要点

  • 按ACOG、ASRM、RCOG和NICE指南,PUL患者MTX给药率分别为2.76%、4.56%、0.41%和35.36%。
  • ACOG和ASRM指南理论上可致4.1/1000(3/724)的潜在存活宫内妊娠误用MTX。
  • 作者认为现行预测异位妊娠高风险的指南可致存活宫内妊娠误用MTX,应审慎使用。

核心结论

  • 现行用于预测PUL人群异位妊娠高风险的指南可导致潜在存活宫内妊娠女性误用MTX。
  • 这些指南应审慎使用以确保无意愿妊娠暴露于MTX,PUL女性应密切监测,妊娠位置未确认时MTX应审慎使用。

研究设计与样本

  • 回顾性观察研究,纳入澳大利亚悉尼Nepean医院早孕门诊2007至2021年连续临床稳定的PUL女性。
  • 共回顾816例PUL女性,其中724例数据完整并纳入最终分析。
  • 将ACOG、ASRM、RCOG和NICE指南中的标准应用于PUL数据库,计算符合MTX给药条件的人数及潜在存活宫内妊娠误用MTX的人数。

主要发现

  • 724例中6例为持续性PUL,其余718例诊断为存活宫内妊娠、非存活宫内妊娠、异位妊娠或失败PUL。
  • 按ACOG、ASRM、RCOG和NICE指南,PUL患者MTX给药率分别为2.76%、4.56%、0.41%和35.36%。
  • ACOG、ASRM和RCOG方案下无持续性PUL接受MTX,NICE方案识别持续性PUL的敏感性为100%。
  • 多数MTX治疗不必要,因这些患者后来被分类为非存活宫内妊娠或失败PUL。
  • 应用ACOG和ASRM指南理论上可致4.1/1000(3/724)的潜在存活宫内妊娠误用MTX。

关键数值与推荐

  • PUL定义为经阴道超声未见宫内妊娠或异位妊娠征象但妊娠试验阳性。
  • 生化行为类似异位妊娠但超声未确认妊娠位置者符合MTX条件以降低后续输卵管破裂风险。
  • 按ACOG、ASRM、RCOG和NICE指南,MTX给药率分别为2.76%、4.56%、0.41%和35.36%。
  • ACOG和ASRM指南理论上致潜在存活宫内妊娠误用MTX率为4.1/1000(3/724)。

临床怎么用

  • 作者认为现行预测PUL人群异位妊娠高风险的指南应审慎使用,以确保无意愿妊娠暴露于MTX。
  • 作者认为PUL女性应密切监测,妊娠位置未确认时MTX应审慎使用。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate the safety of current guidelines on methotrexate (MTX) administration in women with pregnancy of unknown location (PUL) who are considered to have a high risk of underlying ectopic pregnancy (EP), and to investigate whether implementation of these guidelines would result in inadvertent exposure to MTX of viable intrauterine pregnancies (IUPs). METHODS: This was a retrospective observational study of consecutive clinically stable women who were classified with PUL at the early pregnancy unit of Nepean Hospital, Sydney, Australia, between 2007 and 2021. PUL was defined as a positive pregnancy test in the absence of signs of IUP or EP on transvaginal ultrasound. Patients with a PUL that behaved biochemically like an EP, but for which the location of pregnancy was not confirmed on ultrasound, were eligible for MTX to minimize the risk of subsequent tubal rupture. Criteria discussed in the guidelines of the American College of Obstetricians and Gynecologists (ACOG), American Society for Reproductive Medicine (ASRM), Royal College of Obstetricians and Gynaecologists (RCOG) and National Institute for Health and Care Excellence (NICE) were applied to the PUL database. The number of patients eligible to receive MTX and the number with an underlying viable IUP who would be inadvertently prescribed MTX were calculated. RESULTS: A total of 816 women with PUL were reviewed, of whom 724 had complete data and were included in the final analysis. Six patients had persistent PUL and the remaining 718 had a diagnosis of viable IUP, non-viable IUP, EP or failed PUL. According to the ACOG, ASRM, RCOG and NICE guidelines, the rate of MTX administration among patients with PUL would have been 2.76%, 4.56%, 0.41% and 35.36%, respectively. However, no persistent PUL would have received MTX according to the ACOG, ASRM and RCOG protocols (the NICE protocol identified patients with persistent PUL with a sensitivity of 100%), and the majority of MTX treatments were unnecessary because those patients were later classified as having non-viable IUP or failed PUL. Application of ACOG and ASRM guidance could result theoretically in inadvertent MTX administration to women with an underlying viable IUP at a rate of 4.1/1000 (3/724). CONCLUSIONS: Current guidelines used to predict high risk of EP in the PUL population lead to inadvertent MTX administration to women with an underlying viable IUP. These guidelines should be used wisely to ensure that no wanted pregnancy is exposed to MTX. Women with PUL should be monitored carefully, and MTX should be used judiciously when the location of pregnancy is yet to be confirmed. © 2024 The Authors. Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology.

来源:Ultrasound Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Jin CS, Uzuner C, Condous G, et al. Safety of methotrexate administration in women with pregnancy of unknown location at high risk of ectopic pregnancy. Ultrasound Obstet Gynecol. 2024. PMID: 38279942. doi:10.1002/uog.27593

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。